0.256

13.78% 0.031

Mainz Biomed N V (MYNZ)

Overview News Price History Why MYNZ Down? Discussions Forecast

Mainz Biomed N V stock is traded at $0.256, with a volume of 5.25M. It is up +13.78% in the last 24 hours and down -1.16% over the past month. Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

Previous Close:

$0.225

Open:

$0.234

24h Volume:

5.25M

Relative Volume:

1.58

Market Cap:

$15.68M

Revenue:

$895.50K

Net Income/Loss:

$-26.30M

P/E Ratio:

-0.134

EPS:

-1.91

Net Cash Flow:

$-23.84M

1W Performance:

+14.29%

1M Performance:

-1.16%

6M Performance:

-55.22%

1Y Performance:

-76.94%

1-Day Range:

$0.2316

$0.2639

1-Week Range:

$0.19

$0.2639

52-Week Range:

$0.1852

$1.79

Mainz Biomed N V Stock (MYNZ) Company Profile

Name

Mainz Biomed N V

Sector

Healthcare (1200)

Industry

Diagnostics & Research (57)

Phone

Address

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

MYNZ's Discussions on Twitter

Compare MYNZ with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MYNZ Mainz Biomed N V	0.256	15.68M	895.50K	-26.30M	-23.84M	-1.91
TMO Thermo Fisher Scientific Inc	521.66	199.82B	42.37B	6.14B	7.78B	15.26
DHR Danaher Corp	238.83	173.66B	23.74B	3.89B	4.98B	7.93
A Agilent Technologies Inc	138.14	38.64B	6.51B	1.29B	1.37B	3.82
IQV Iqvia Holdings Inc	201.43	36.52B	15.32B	1.41B	1.96B	5.95
IDXX Idexx Laboratories Inc	421.76	34.55B	3.84B	866.24M	792.60M	9.80

Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-21-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-21-22	Initiated	H.C. Wainwright	Buy

Mainz Biomed N V Stock (MYNZ) Latest News

Nov 27, 2024

Mainz Biomed (NASDAQ:MYNZ) Rating Lowered to “Neutral” at HC Wainwright - Defense World

Nov 27, 2024

Nov 25, 2024

What You Didn’t Know About Mainz Biomed N.V (NASDAQ: MYNZ) This Week - Stocks Register

Nov 25, 2024

Nov 22, 2024

Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test - Nasdaq

Nov 22, 2024

Nov 19, 2024

Mainz Biomed and Thermo Fisher Scientific sign a collaboration agreement - Wiley

Nov 19, 2024

Nov 15, 2024

Mainz Biomed Considers Reverse Stock Split for Nasdaq Compliance - TipRanks

Nov 15, 2024

MAINZ BIOMED NV- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com

Nov 15, 2024

Nov 13, 2024

Thermo Fisher Scientific and Mainz Biomed Partner to Advance Colorectal Cancer Screening Technology - Citybuzz

Nov 13, 2024

Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening - Nasdaq

Nov 13, 2024

Nov 12, 2024

Mainz Biomed N.V. and Thermo Fisher Scientific Inc. Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets - Marketscreener.com

Nov 12, 2024

Mainz Biomed Partners With Thermo Fisher To Advance Colorectal Cancer Screening - Contract Pharma

Nov 12, 2024

Mainz Biomed and Thermo Fisher Scientific Sign a - GlobeNewswire

Nov 12, 2024

Mainz Biomed Partners with Thermo Fisher for Next-Gen Cancer Screening Breakthrough | MYNZ Stock News - StockTitan

Nov 12, 2024

Oct 22, 2024

Is Now The Time To Buy Mainz Biomed N.V. (NASDAQ: MYNZ) Stock? - Stocks Register

Oct 22, 2024

Mainz Biomed’s half-yearly revenue increases 4% YoY - Medical Buyer

Oct 22, 2024

Mainz Biomed restructured operations, implemented cost reductions - Yahoo Finance

Oct 22, 2024

Oct 21, 2024

Mainz Biomed reports revenue growth and reduced losses By Investing.com - Investing.com South Africa

Oct 21, 2024

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Oct 21, 2024

Oct 18, 2024

Mainz Biomed N : MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Form 6 K - Marketscreener.com

Oct 18, 2024

Oct 16, 2024

Financial Metrics Unveiled: Mainz Biomed N.V. (MYNZ)’s Key Ratios in the Spotlight - The Dwinnex

Oct 16, 2024

Oct 15, 2024

Mainz Biomed N.V.: Navigating Market Fluctuations with a 5.69M Market Cap - The InvestChronicle

Oct 15, 2024

Stocks of Mainz Biomed N.V. (MYNZ) are poised to climb above their peers - SETE News

Oct 15, 2024

Oct 14, 2024

Evaluating MYNZ’s financial ratios for a profitable investment - US Post News

Oct 14, 2024

Oct 11, 2024

Investors’ Faith in Mainz Biomed N.V. (MYNZ) could reap rewards if they hold on for the long haul - US Post News

Oct 11, 2024

Oct 10, 2024

Mainz Biomed Secures Additional $1.5M Funding - Yahoo Finance

Oct 10, 2024